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Abstract The importance of three conserved transmembrane
prolines of the human vasoactive intestinal polypeptide (VPAC)1
receptor was examined by single alanine substitution. P266A,
P300A and P348A reduced the expression level, but maintained
the binding to VIP. P266A showed decreased ability to stimulate
cAMP, while P300A and P348A displayed an increased potency
in cAMP production combined with a high sensitivity towards
GTP compared to the wild type receptor. In addition, substitu-
tions of two conserved leucines located in position 32 and +1
from P348 were investigated. L346A and L349A reduced the
receptor expression, influenced the G protein coupling and
decreased the receptor activity. These observations, which are the
first on conserved transmembrane prolines within this family of
receptors, indicate that these residues are important for receptor
expression, G protein coupling and receptor activity. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
The human vasoactive intestinal polypeptide (VIP)/pituitary
adenylate cyclase activating polypeptide (PACAP) receptor 1
(hVPAC1R) is a member of the Class B family (the secretin
receptor family) of seven transmembrane, GTP binding pro-
tein (G protein)-coupled receptors [1]. Receptors within this
family are characterized by large N-terminal extracellular do-
mains, which major functions are binding to peptide ligands.
hVPAC1R is activated by interaction with the widely distrib-
uted neuropeptides VIP and PACAP [2,3]. The VPAC1 recep-
tor binds VIP and PACAP with similar a⁄nities and stimu-
lates the production of cAMP via coupling to a Gs protein
and stimulation of adenylate cyclase. The secretin receptor
family has certain structural features in common with the
large rhodopsin family (Class A), such as seven hydrophobic
transmembrane helices arranged in the same anticlockwise
manner (seen from the extracellular space) [4], a disul¢de
bridge between extracellular loop 1 and loop 2 [4,5] and few
conserved positions in the transmembrane regions [4]. There-
fore, it seems reasonable to postulate a kind of structural and
functional similarity between these families. While there is
considerable data supporting important roles of conserved
prolines in TM5, TM6 and TM7 in the rhodopsin family,
less is known about these residues, which are localized in
TM4, TM5 and TM6, within the secretin receptor family.
Although both families have conserved prolines in TM5 and
TM6, the location is di¡erent. Compared to the rhodopsin
family, the conserved proline of TM5 in the secretin receptor
family is placed eight residues towards the extracellular space
and the proline of TM6 is placed eight residues towards the
intracellular space [4]. From our suggested arrangement of the
seven transmembrane helices within the secretin receptor fam-
ily [4], P266 is supposed to face the interhelical region between
TM3, TM4 and TM5, while P300 (TM5) presumably is in
close contact with TM4 near the extracellular surface and
¢nally, P348 in TM6 may be facing the membrane bilayer
in the middle of the helix.
Proline is unique among the amino acids, as its cyclic pyr-
rolidine ring structure prevents it from forming the normal
backbone hydrogen bond of a K-helix. This property is be-
lieved to introduce a kink in the K-helical structure, which due
to helix^helix interactions may contribute to a dynamic pro-
tein structure [6]. Several studies of receptors within the rho-
dopsin family have shown that the proline residues are in-
volved in conformational changes occurring during receptor
activation [7]. Especially, the conserved proline in TM6 par-
ticipates when receptor activation changes the kink angle,
from a large kink in the inactive receptor form to a signi¢-
cantly smaller kink in the active form [8,9]. This property of
£exibility emerges as a key factor in the G protein coupling
and signal transduction.
Until now, there is no information of this unique amino
acid in the human VPAC1 receptor or within the secretin
receptor family as general. In this study we examined the
role of these conserved transmembrane prolines in hVPAC1R
for receptor expression, ligand binding, G protein coupling
and receptor activation by site-directed mutagenesis. We sub-
stituted single prolines with alanine to introduce a neutral and
small size amino acid with a helix forming proportion in con-
trast to the helix destabilizing property of proline. In addition
and due to earlier observation concerning the importance of
residues in TM6 for receptor activation, we also changed two
conserved leucines in the proximity of P348 (TM6).
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2. Materials and methods
2.1. Materials
The cDNA encoding the human VPAC1 receptor was kindly do-
nated by Dr. A. Couvineau, Institute National de la Sante¤ et de la
Recherche Me¤dicale, INSERM, France. VIP was purchased as cus-
tom synthesis (Bachem; Torrance, CA, USA), Peninsula Laboratories
(Belmont, CA, USA). Restriction enzymes were from Medinova,
Amersham and Promega. Primers were synthesized by DNA Technol-
ogies (Aarhus, Denmark). Pwo-polymerase used for PCR was pur-
chased from Boehringer Mannheim. Human embryonic kidney 293
cells (HEK293 cells) were obtained from ATCC (American Type Cul-
ture Collection). Cell culture reagents and bu¡ers were purchased
from Life Technologies (Roskilde, Denmark) and In Vitro (Fredens-
borg, Denmark). The multiscreen assay system and the ¢lter plates
were from Millipore, Denmark. The cAMP radioimmunoassay kit
was from Amersham Life Science.
2.2. Receptor constructs and site-directed mutagenesis
The coding region of the human VPAC1 receptor cDNA was sub-
cloned as a HindIII-XbaI fragment into the expression vector
pcDNA3 (Invitrogen). hVPAC1 receptor mutants were generated by
site-directed mutagenesis made by overlap extension method [10] us-
ing two unique restriction sites P£MI^Sse8387I (P300A, L346A,
P348A and L349A) and Bsu36I^NheI (P266A) to introduce the mu-
tated segment. In several of the mutant primers a silent mutation was
introduced, which either includes or excludes a restriction enzyme site.
Identi¢cation of all the mutants was made after the ¢rst transforma-
tion step by restriction enzyme digestion and later con¢rmed by di-
deoxy chain termination DNA sequencing.
2.3. Cell culture and transient transfection
HEK293 cells were grown in MEM ^ minimum essential medium
(with Earl’s salts and without glutamine), supplemented with 10%
fetal calf serum, 2 mM glutamine and 1x gentamicin or penicillin/
streptomycin. HEK293 cells were plated in 200 mm dishes (4U106
cells/dish) and transiently transfected with hVPAC1R cDNA encoding
wild type/mutant receptors, using the calcium-phosphate precipitation
method. Control plates were made by transfecting HEK293 cells with
5 Wg of vector DNA (pcDNA3)/200 mm plate. Wild type and mutant
producing cells were made by transfection with 2^10 Wg of cDNA/200
mm plate. Cells were harvested 72 h after transfection. Transfection
e⁄ciency was estimated by co-transfection of all the mutants/wild type
with cDNA encoding L-galactosidase. The amount of L-galactosidase
was de¢ned as unit L-galactosidase/mg protein. The protein concen-
tration was estimated by the Bradford method (Bio-Rad).
2.4. Preparation of plasma membranes
Cells from a con£uent 200 mm culture plate were rinsed with phos-
phate bu¡ered saline (PBS) and scraped o¡ in the same bu¡er for
centrifugation. After centrifugation, the supernatant was resuspended
in 15 ml binding bu¡er containing 20 mM HEPES, 2 mM CaCl2, 1.5
mM NaCl, 5 mM EDTA and 1 mg/ml bacitracin. The cell suspension
was homogenized with a polythron for 30 s, centrifuged at 20 000Ug
for 20 min and resuspended in 15 ml binding bu¡er. The procedure
was repeated once and the membranes were resuspended in binding
bu¡er and stored at 380‡C.
2.5. Binding assay
The binding a⁄nities of wild type and mutant hVPAC1 receptors
were analyzed by [125I]VIP binding to plasma membranes from trans-
fected cells. VIP was labeled and puri¢ed as described by Martin et al.
[11]. Competitive binding analysis, with a constant amount of radio-
iodinated peptide (10310 M) and increasing amount of non-radiola-
beled peptide (0^1036 M) was set up in order to determine the total
number of binding sites (Bmax) and the binding a⁄nity, represented by
the inhibitory constant, IC50. The binding assay was performed using
a multiscreen assay system with 0.45 Wm surfactant-free mixed cellu-
lose, ester membranes. The membrane plates were preincubated with
200 Wl 0.5% polyethyleneimine (PEI) for a minimum of 3 h at 4‡C.
After preincubation, the coating solution was removed by ¢ltration
and the plates were washed three times with ice cold binding bu¡er.
Binding was performed using 100 Wl membrane preparation (10^100
Wg membrane protein), VIP tracer and increasing concentrations of
unlabeled VIP in a total volume of 150 Wl, and were incubated for
60 min at room temperature under gentle mixing. The binding assay
was terminated by applying vacuum to the ¢lter plates and washed
with ice cold binding bu¡er. The ¢lters were dried, punched out and
the bound radioactivity was quanti¢ed in a Q-counter. To determine
the e¡ect of GTP on VIP binding, membranes were incubated with
GppNHp or GTPQS in a total concentration of 10 WM and with
[125I]VIP and non-radiolabeled VIP as mentioned above.
2.6. Biological activity
The functional properties of wild type and mutant receptors were
investigated by intracellular cAMP measurements using a [125I]cAMP
assay kit. HEK293 cells were transfected with the human VPAC1
receptor and seeded to 2U105 cells/well in 24 well culture dishes
coated with poly-D-lysine 48 h after transfection. Cells were washed
after further 24 h with Dulbecco’s PBS medium (DPBS) and incu-
bated with 500 Wl (DPBS)-medium containing 0.1 mM isobutyl-meth-
ylxanthine (IBMX) for 15 min at 37‡C and for a further 20 min at
37‡C with VIP in increasing concentrations (0^1036 M). cAMP was
extracted by incubating the cells with 50 Wl trichloroacetic acid (10%)
and neutralized by 50 Wl 0.8 M Tris-base. The generation of standard
curves and the measurement of cAMP levels in supernatant of cell
lysates were performed following the manual from Amersham Life
Science. All the mutants had a basal cAMP level comparable with
the wild type receptor, excluding detectable changes in constitutive
activity. HEK293 cells transfected with pcDNA3 without receptor
insert did not show any VIP-stimulated cAMP production, indicating
absence of endogenous VIP-sensitive receptors.
2.7. Data analysis
This study is a comparison of wild type and alanine substitutions,
investigated under the same assay conditions. The apparent binding
a⁄nity was measured as IC50, while the e¡ect of a particular mutation
is presented relative to wild type, i.e. IC50(mutant)/IC50(wild type). To
obtain the actual IC50, the binding curves were ¢tted to the following
four parameter, one step equation: Y = A+(B3A)/((1+X/IC50)D),
where A is non-speci¢c binding, B is the maximum binding, D is
the slope of the curve and X is log VIP(M). The VIP-induced
cAMP production was measured as EC50, while the functional e¡ect
of a particular mutation is presented relative to wild type, i.e.
EC50(mutant)/EC50(wild type). The cAMP curves were ¢tted to the
same equation as the binding curves to obtain the actual EC50 value,
but with A as the basal level of produced cAMP and B as the max-
imum level of produced cAMP. All observations were repeated at
least four times in independent experiments.
Bmax was calculated according to the equation presented by Akera
and Cheng [12]. Due to transient transfection, the transfection e⁄-
ciency varied from experiment to experiment. Therefore the average
Fig. 1. Schematic secondary topology model of the human VPAC1
receptor. The investigated residues of transmembrane helices TM4,
TM5 and TM6 are indicated as black circles (P266, P300 and P348)
and gray circles (L346, L349) with projection to letters in bold be-
low the model. All helices are de¢ned to have a length of 24 resi-
dues and residue numbers were set by determining the center of
each helix in the lipid membrane as previously described [4].
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Bmax value for the wild type receptor was normalized to 1 for each
transfection, and the values for all the mutants are presented as frac-
tions of wild type.
3. Results
To elucidate the role of conserved transmembrane prolines
of the hVPAC1 receptor (for model see Fig. 1), three prolines
(P266, P300 and P348) located in TM4, TM5 and TM6, re-
spectively, were substituted individually with alanine.
The expression levels of all the selected positions were re-
duced to 15^20% of the wild type receptor expression (Fig. 2).
None of the investigated mutants did a¡ect the VIP binding,
but several of them disturbed the G protein coupling and
receptor activity. By adjusting the amount of DNA in the
transfection step, it was possible to obtain a similar expression
level (2^3 pmol/mg protein) for all the investigated mutants
and the wild type receptor. Thereby it became possible to
Fig. 2. Receptor expression, Bmax, of wild type and mutant recep-
tors. The expression level of the wild type receptor was normalized
to 100%, while all the mutant data were presented relative to this
value. Data points represent the mean þ S.E.M. of four or ¢ve ex-
periments.
Fig. 3. E¡ects of GTPQS on [125I]VIP binding to wild type and mutant VPAC1 receptors. Binding to membranes prepared from transient trans-
fected HEK293 cells expressing wild type and mutant receptors in the absence or presence of GTPQS as described under Section 2.
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compare the functional data, as it is well known that the
expression level in£uences the receptor activity [20]. The func-
tionality was measured by VIP-mediated cAMP production in
transiently transfected HEK293 cells. P300A and P348A dis-
played a 3 and 10 fold increased ability, respectively, while
P266A, L346A and L349A decreased the potency by 24, 20
and 100 fold, respectively (Table 1). As a consequence of these
results, the ability of the investigated mutant receptors to
interact with G proteins was evaluated by measuring the e¡ect
of GTPQS on [125I]VIP binding to cell membranes. Addition of
GTPQS reduced the total agonist binding of the wild type
receptor with almost 50% and thereby shifted the binding
a⁄nity from high a⁄nity binding to low a⁄nity binding,
i.e. an uncoupling of the G protein. The GTP sensitivity of
P300A and P348A was increased compared to the wild type,
showing a total binding reduction of 70% (Fig. 3), consistent
with the improved ability of these mutants to mediate cAMP
production (Table 1). L349A was less a¡ected by GTP treat-
ment, showing a reduction of about 40% (Fig. 3), which
agreed with the impaired cAMP activity (Table 1). Addition
of GTPQS to L346A and P266A had almost similar e¡ects as
on the wild type receptor (Fig. 3).
4. Discussion
The functional role of three conserved prolines in the trans-
membrane helices of the human VIP/PACAP receptor 1
(hVPAC1R) was investigated in terms of their surface expres-
sion, VIP binding, G protein coupling and VIP-induced acti-
vation. Mutations at the three positions had only minor in-
£uence on the binding a⁄nity, but the signaling properties
were signi¢cantly altered.
P266A, P300A and P348A reduced the receptor expression
markedly, which is in agreement with studies on G protein
coupled receptors within the Class A family [13^15]. The
mechanism behind the impaired receptor expression of the
mutants remains to be clari¢ed, but for other receptors it
has been suggested to be due to receptor misfolding in the
endoplasmic reticulum and the regulation of this process by
chaperones [14].
Concerning the VIP-stimulated cAMP production, P266A
reduced the receptor activity by V20 fold, suggesting a desta-
bilizing e¡ect on the receptor conformation. P266 is placed in
a conserved motif (GWGXP), where it could be involved in a
kink formation. A similar pattern has been described for the
voltage-gated channel forming peptides alamethicin and me-
littin, where the motifs G-X-X-P and G-X-P, respectively, are
found within the central portion of the helix. Alanine substi-
tutions show that the high amplitude bending motion for
alamethicin can be attributed to this motif [16].
Contrary to P266A, P300A and P348A increased the activ-
ity of cAMP production corresponding to an increase in the
rate constant for shifting RCR*, i.e. P300A and P348A sta-
bilize the high a⁄nity receptor conformation. One interpreta-
tion could be that these prolines have a constraining role in
the receptor by preventing an activation and interaction with
the G protein. The experiment with addition of GTP ana-
logues support this notion, since the GTP sensitivity of
P300A and P348A were increased compared to the wild
type receptor. P300 and P348 could have a structural stabiliz-
ing e¡ect involved in the G protein coupling mechanism,
which for P348 (TM6) correlate to studies of receptors within
the rhodopsin family [7,9]. For further investigation, we sub-
stituted two conserved leucines, localized in position 32 and
+1 from P348, with alanine. The results of L346A and L349A
seem to support the importance of the area surrounding P348,
when both positions a¡ected the ligand-mediated receptor ac-
tivation. Based on our suggested arrangement of the seven
transmembrane helices [4], P348 is supposed to face the lipid
bilayer while L346 and L349 are oriented towards TM7 and
probably in£uenced by the bulky pyrrolidine ring of proline.
Thus, L346 and L349 could have a central role in helix^helix
interaction between TM6 and TM7.
Several studies within the rhodopsin family have shown
transmembrane prolines to play important roles in receptor
expression, ligand binding, helix £exibility, receptor activity
and G protein coupling. However, it is very di⁄cult to draw
parallels to the secretin receptor family when the pattern of
sequences is di¡erent, i.e. the conserved prolines in Class A
receptors are in TM5, TM6 and TM7, while conserved pro-
lines within the secretin receptor family (Class B) are localized
in TM4, TM5 and TM6. [13,17^19].
In summary, this study describes the importance of con-
served transmembrane prolines in receptor expression, ligand
binding, G protein coupling and receptor activation within the
hVPAC1 receptor. The impaired activity of P266A connected
to the reduced receptor expression and improved receptor
activity of P300A and P348A suggest that these prolines are
essential determinants in several aspects of the activating
mechanism.
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